Dianthus Therapeutics, Inc.
US ˙ NasdaqCM ˙ US2528281080

SecurityDNTH / Dianthus Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership781,282 shares
Latest Disclosed Value $ 65,565,185
UBS Group AG reports 28.79% increase in ownership of DNTH / Dianthus Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 781,282 shares of Dianthus Therapeutics, Inc. (US:DNTH) valued at $65,565,185 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 606,620 shares of Dianthus Therapeutics, Inc.. This represents a change in shares of 28.79% during the quarter. The current value of the position is $66,385,532 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F DIANTHUS THERAPEUTICS COM 252828108 781,282 174,662 28.79 65,565 162.28 0.0018
2026-01-29 2025-12-31 13F DIANTHUS THERAPEUTICS COM 252828108 606,620 469,547 342.55 24,999 363.53 0.0041
2025-11-13 2025-09-30 13F DIANTHUS THERAPEUTICS COM 252828108 137,073 5,592 4.25 5,394 120.21 0.0008
2025-08-14 2025-06-30 13F DIANTHUS THERAPEUTICS COM 252828108 131,481 84,052 177.22 2,449 184.77 0.0004
2025-05-13 2025-03-31 13F DIANTHUS THERAPEUTICS COM 252828108 47,429 -6,432 -11.94 860 -26.75 0.0002
2025-02-14 2024-12-31 13F DIANTHUS THERAPEUTICS COM 252828108 53,861 25,433 89.46 1,174 50.90 0.0002
2024-11-14 2024-09-30 13F DIANTHUS THERAPEUTICS COM 252828108 28,428 20,019 238.07 778 258.53 0.0002
2024-08-14 2024-06-30 13F DIANTHUS THERAPEUTICS COM 252828108 8,409 -6,096 -42.03 218 -50.11 0.0001
2024-05-13 2024-03-31 13F DIANTHUS THERAPEUTICS COM 252828108 14,505 14,125 3,717.11 435 14,400.00 0.0001
2024-02-09 2023-12-31 13F DIANTHUS THERAPEUTICS COM 252828108 380 61 19.12 4 -25.00 0.0000
2023-11-09 2023-09-30 13F DIANTHUS THERAPEUTICS COM 252828108 319 319 4 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.